UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)

Clinical & translational oncology, 2019-01, Vol.21 (1), p.3-17

2019

Volltextzugriff (PDF)

SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)

Clinical & translational oncology, 2021-05, Vol.23 (5), p.980-987

2021

Volltextzugriff (PDF)

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

British journal of cancer, 2008-05, Vol.98 (10), p.1608-1613

2008

Volltextzugriff (PDF)

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Clinical & translational oncology, 2020-06, Vol.22 (6), p.823-834

2020

Volltextzugriff (PDF)

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

Clinical & translational oncology, 2015-12, Vol.17 (12), p.1020-1029

2015

Volltextzugriff (PDF)

Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus

Clinical & translational oncology, 2021-07, Vol.23 (7), p.1304-1313

2021

Volltextzugriff (PDF)

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus

Clinical & translational oncology, 2020-05, Vol.22 (5), p.759-771

2020

Volltextzugriff (PDF)

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Annals of oncology, 2020-12, Vol.31 (12), p.1734-1745

2020

Volltextzugriff (PDF)

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013

Clinical & translational oncology, 2013-12, Vol.15 (12), p.977-984

2013

Volltextzugriff (PDF)

SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)

Clinical & translational oncology, 2016-12, Vol.18 (12), p.1237-1242

2016

Volltextzugriff (PDF)

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Annals of oncology, 2023-10, Vol.34 (10), p.920-933

2023

Volltextzugriff (PDF)

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

Annals of oncology, 2023-05, Vol.34 (5), p.468-476

2023

Volltextzugriff (PDF)

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

Annals of oncology, 2019-02, Vol.30 (2), p.290-296

2019

Volltextzugriff (PDF)

Fructose transporter GLUT5 expression in clear renal cell carcinoma

Oncology reports, 2011-02, Vol.25 (2), p.315-323

2011

Volltextzugriff (PDF)

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)

Clinical microbiology and infection, 2018-06, Vol.24, p.S41-S52

2018

Volltextzugriff (PDF)

Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group

Lung cancer (Amsterdam, Netherlands), 2020-09, Vol.147, p.83-90

2020

Volltextzugriff (PDF)

Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer

Clinical & translational oncology, 2007-11, Vol.9 (11), p.694-702

2007

Volltextzugriff (PDF)

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial

JAMA oncology, 2021-12, Vol.7 (12), p.e214761

2021

Volltextzugriff (PDF)

Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial

Lung cancer (Amsterdam, Netherlands), 2023-11, Vol.185, p.107376-107376, Article 107376

2023

Volltextzugriff (PDF)

Correction to: Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Clinical & translational oncology, 2020-06, Vol.22 (6), p.961-962

2020

Volltextzugriff (PDF)

A consensus statement on the gender perspective in lung cancer

Clinical & translational oncology, 2017-05, Vol.19 (5), p.527-535

2017

Volltextzugriff (PDF)

Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)

ESMO open, 2021-04, Vol.6 (2), p.100048-100048, Article 100048

2021

Volltextzugriff (PDF)

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Annals of oncology, 2022-02, Vol.33 (2), p.181-192

2022

Volltextzugriff (PDF)

Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

Clinical & translational oncology, 2017-03, Vol.19 (3), p.341-356

2017

Volltextzugriff (PDF)

Erratum to: Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

Clinical & translational oncology, 2017-04, Vol.19 (4), p.525-525

2017

Volltextzugriff (PDF)

1 – 25 von 336

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(312)
Mit Volltextzugriff
(316)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(109)
Life Sciences & Biomedicine
(86)
Humans
(72)
Oncology
(51)
Male
(44)
Female
(35)
Middle Aged
(34)
Aged
(30)
Adult
(23)
Chemistry
(23)
Physical Sciences
(21)
Aged, 80 And Over
(20)
Chemistry, Physical
(20)
Medicine
(19)
Medicine & Public Health
(18)
Prognosis
(18)
Hematology, Oncology And Palliative Medicine
(16)
Treatment Outcome
(13)
Biological And Medical Sciences
(12)
Exact Sciences And Technology
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(18)

Menü

Weitere Dienste

Einstellungen

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)

SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013

SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

Fructose transporter GLUT5 expression in clear renal cell carcinoma

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)

Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group

Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial

Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial

Correction to: Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

A consensus statement on the gender perspective in lung cancer

Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

Erratum to: Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

Suchergebnisse filtern